A case for treating high hepatitis B DNA levels before starting HIV therapy [3]

AIDS

Volumn 20, Issue 18, 2006, Pages 2402-2403

  Baker, Jason V ^a   Boulware, David R ^a   Bohjanen, Paul R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ATAZANAVIR; CD4 ANTIGEN; EFAVIRENZ; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ADULT; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMORBIDITY; DISEASE EXACERBATION; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFECTION CONTROL; INFLAMMATORY DISEASE; LETTER; MALE; NONHUMAN; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; TREATMENT RESPONSE; TUBERCULOSIS; VIRUS INHIBITION; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; GUANINE; HEPATITIS B; HIV INFECTIONS; HUMANS; IMMUNE SYSTEM DISEASES; MALE; SYNDROME;

EID: 33751241415     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280110aef     Document Type: Letter

References (10)

1. Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19:221-240.
2. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593-601.
3. Shelburne SA , Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003; 5:67-79.
4. Carr A, Cooper DA. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997; 349:995-996.
5. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004; 39:129-132.
6. Zoulim F, Poynard T, Degos F, Slama A, El Hasnaoui A, Blin P, et al. A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine. J Viral Hepat 2006; 13:278-288.
7. Shelburne SA, Visnegarwala F, Darcourt J, Graviss EA, Giordano TP, White C , Hamill RJ. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
8. Wendel KA, Alwood KS, Gachuhi R, Chaisson RE, Bishai WR, Sterling TR. Paradoxical worsening of tuberculosis in HIV-infected persons. Chest 2001; 120:193-197.
9. Lortholary O, Fontanet A, Memain N, Martin A, Sitbon K, Dromer F. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043-1049.
10. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73.